Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label study of VG2025 in advanced intrahepatic cholangiocarcinoma
CTR20261992Phase 2Active
- Sponsor
- Virogin Biotech
- Start
- Aug 2026
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of VG2025 in intrahepatic cholangiocarcinoma (ICC), sponsored by Virogin Biotech. Started Aug 2026; status: active.
02
Drugs
VG2025
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on CTR20261992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261992.